Pembrolizumab, also known as Keytruda, has been approved by the FDA for the treatment of stage 3-4a cervical cancer in combination with chemoradiation therapy. This marks the 40th indication for the drug, which has been used to treat 19 different types of cancer. The approval was based on a trial showing that patients receiving pembrolizumab had a higher progression-free survival rate compared to those receiving a placebo. Common side effects of the drug include nausea, diarrhea, and fatigue. Pembrolizumab should be administered before chemoradiotherapy when given on the same day.
Source link
FDA Approves Pembrolizumab for Stage 3/4a Cervical Cancer
